Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Dragon Pharma Sells EPO Unit

publication date: Nov 16, 2007
Dragon Pharmaceuticals has sold its EPO business to an unidentified purchaser for $2.1 million. Pointing out that the product contributed just 3% of its revenues, Dragon said it preferred to concentrate on its higher growth antibiotics business. A market study, according to Dragon, shows the EPO market may be trending lower over the next three years. Dragon also announced that antibiotic sales have increased from $31.2 million for all of 2005 to about $60 million for just the first nine months of 2007, which was a 60% increase over the comparable 2006 figure. More details...

Stock Symbol: (OTCBB: DRUG)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital